NASDAQ · LTRN
Healthcare · Biotechnology
$2.34
Up+$0.05 (+2.18%)
Updated Aug 22, 2026, 6:45 PM
SID Score
2.6/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
LTRN closed at $2.34 after 21 trading sessions, down 14.91% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $2.32 | $2.41 | $2.13 | $2.34 | 185.08K |
| Aug 20, 2026 | $2.45 | $2.515 | $2.25 | $2.29 | 169.08K |
| Aug 19, 2026 | $2.54 | $2.83 | $2.405 | $2.49 | 242.67K |
| Aug 18, 2026 | $2.53 | $2.59 | $2.475 | $2.52 | 69.33K |
| Aug 17, 2026 | $2.59 | $2.65 | $2.485 | $2.60 | 108.04K |
| Aug 14, 2026 | $2.51 | $2.74 | $2.35 | $2.65 | 165.69K |
| Aug 13, 2026 | $2.65 | $2.7791 | $2.60 | $2.63 | 104.47K |
| Aug 12, 2026 | $2.83 | $2.85 | $2.61 | $2.66 | 122.88K |
| Aug 11, 2026 | $2.81 | $2.87 | $2.74 | $2.78 | 50.89K |
| Aug 10, 2026 | $2.81 | $2.86 | $2.72 | $2.81 | 71.88K |
| Aug 7, 2026 | $2.90 | $2.92 | $2.80 | $2.86 | 61.22K |
| Aug 6, 2026 | $2.76 | $2.90 | $2.71 | $2.78 | 35.9K |
| Aug 5, 2026 | $2.78 | $2.8798 | $2.735 | $2.80 | 52.62K |
| Aug 4, 2026 | $2.73 | $2.8753 | $2.6545 | $2.75 | 82.99K |
| Aug 3, 2026 | $2.68 | $2.83 | $2.58 | $2.61 | 115.17K |
| Jul 31, 2026 | $2.72 | $2.87 | $2.57 | $2.63 | 47.91K |
| Jul 30, 2026 | $2.51 | $2.75 | $2.51 | $2.65 | 77.12K |
| Jul 29, 2026 | $2.58 | $2.7697 | $2.51 | $2.51 | 36.47K |
| Jul 28, 2026 | $2.79 | $2.865 | $2.60 | $2.60 | 65.49K |
| Jul 27, 2026 | $2.77 | $2.90 | $2.7589 | $2.79 | 38.53K |
| Jul 24, 2026 | $2.87 | $2.885 | $2.73 | $2.75 | 63.73K |
The latest Smart Investors Daily articles mentioning LTRN.
LTRN research
Company profile and research snapshot.
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Apr 2, 2025 | Lake Street | Buy | — |
| Apr 25, 2024 | HC Wainwright & Co. | Neutral | — |
| Aug 10, 2023 | EF Hutton | Buy | — |
| Jun 26, 2023 | EF Hutton | Buy | — |
| May 18, 2023 | HC Wainwright & Co. | Neutral | — |
No generated briefing is available yet.
Benzinga · Jul 23, 2026
The United States Patent and Trademark Office has issued Lantern Biopharma a Notice of Allowance for U.S. Patent Application No. 17/230,821, titled "Methods for the Treatment of Solid Tumor Cancers Using Illudins
businesswire.com · Dec 3, 2025
DALLAS--(BUSINESS WIRE)--LP-184 Clinical Insights, KOL Webinar & Future Plans.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning LTRN.
